The injectable weight loss drugs known as GLP-1 agonists have taken the world by storm. And the stocks of the companies making the drugs have crushed the market over the past couple of years. However, an industrywide shortage for the drugs opened the door for companies like Hims & Hers Health (NYSE: HIMS) to compete by offering lower-priced compounded versions mixed up by their teams.

Hims & Hers stocks took flight once the company announced it was bringing compounded GLP-1 agonists to market.

However, there is speculation that the shortage could end, and Hims & Hers has fallen back to earth since announcing its second-quarter earnings on Aug. 5.

Continue reading

Source Fool.com